Cargando…
Recombinant Bispecific Antibodies to the Human ErbB2 Receptor and Interferon-Beta
The development of and research into new therapies that can selectively and effectively destroy tumor cells that overexpress the ErbB2 receptor is a pressing task. Recently, research into the use of type I interferons in the treatment of cancer has intensified. Cytokine therapy is aimed at activatin...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
A.I. Gordeyev
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385087/ https://www.ncbi.nlm.nih.gov/pubmed/32742732 http://dx.doi.org/10.32607/actanaturae.10903 |